Q2 EPS Forecast for Nurix Therapeutics Increased by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for Nurix Therapeutics in a research report issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.84) per share for the quarter, up from their previous estimate of ($0.93). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($3.54) EPS and FY2026 earnings at ($3.37) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter last year, the business posted ($0.76) EPS.

Several other equities analysts have also commented on the stock. Morgan Stanley increased their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, February 3rd. Stephens reaffirmed an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Leerink Partners assumed coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a “market perform” rating and a $16.00 price objective on the stock. Finally, Wells Fargo & Company dropped their target price on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.44.

Nurix Therapeutics Stock Performance

NRIX stock opened at $9.14 on Friday. The firm has a fifty day moving average price of $14.03 and a 200 day moving average price of $19.18. Nurix Therapeutics has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The firm has a market cap of $696.80 million, a PE ratio of -3.16 and a beta of 2.23.

Institutional Investors Weigh In On Nurix Therapeutics

Several hedge funds have recently made changes to their positions in the company. FMR LLC raised its holdings in shares of Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company’s stock valued at $200,349,000 after acquiring an additional 10,047,329 shares in the last quarter. RA Capital Management L.P. bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $25,120,000. Soleus Capital Management L.P. lifted its position in shares of Nurix Therapeutics by 97.3% in the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock worth $39,617,000 after purchasing an additional 1,036,999 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Nurix Therapeutics in the 4th quarter worth approximately $16,447,000. Finally, Boxer Capital Management LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $10,608,000.

Insider Transactions at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,326 shares of company stock worth $213,449. Insiders own 9.80% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.